13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001515070
Total reported value
$635.1M
$635.1M
28 檔
58.0%
The Q4 2025 SEC filing reveals that Tetragon Partners GP Ltd held a total portfolio value of $635.1M, covering 28 public equity positions.
In Q4 2025, Tetragon Partners GP Ltd adopted a defensive or profit-taking posture, trimming 6 positions and completely liquidating 24 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including PATH, KGEI, LYFT) accounted for 58.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
PRAX
市值: $6.8M
Top Position Liquidated / Trimmed
BABA 0.5 06-01-31
前期市值: $174.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PATH | Uipath Inc - Class A | Stock-Tech | 60.30% | -1.34% | +2.95% | |
| 2 | KGEI | Kolibri Global Energy Inc | Stock-Other | 5.75% | -1.95% | -1.92% | |
| 3 | LYFT | Lyft Inc-a | Stock-Tech | 4.08% | -0.28% | — | |
| 4 | AUTL | Autolus Therapeutics PLC | Stock-Other | 3.99% | -0.16% | — | |
| 5 | CXM | Sprinklr Inc-a | Stock-Other | 3.61% | -0.77% | — | |
| 6 | WK | Workiva Inc | Stock-Tech | 2.73% | -0.98% | — | |
| 7 | ANNX | Annexon Inc | Stock-Other | 2.15% | -0.27% | -3.79% | |
| 8 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.43% | -1.00% | EXIT | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.40% | -0.22% | -19.70% | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.36% | +0.12% | +18.44% | |
| 11 | PHVS | Pharvaris N.V. | Stock-Other | 1.14% | +0.39% | — | |
| 12 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.04% | -0.46% | -42.02% | |
| 13 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.02% | +0.34% | +11.12% | |
| 14 | MBX | Mbx Biosciences Inc | Stock-Other | 0.95% | +0.93% | -19.41% | |
| 15 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.94% | — | — | |
| 16 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.93% | +0.41% | — | |
| 17 | IMVT | Immunovant Inc | Stock-Other | 0.89% | +0.50% | -11.78% | |
| 18 | ALKS | Alkermes plc | Stock-Healthcare | 0.83% | +0.47% | +57.54% | |
| 19 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.78% | — | +115.14% | |
| 20 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.69% | +0.01% | +5.65% | |
| 21 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.65% | +0.50% | — | |
| 22 | NKTR | Nektar Therapeutics | Stock-Other | 0.62% | -0.48% | — | |
| 23 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.61% | +0.16% | +142.59% | |
| 24 | MPLT | Maplight Therapeutics Inc | Stock-Other | 0.61% | -0.44% | EXIT | |
| 25 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.47% | +1.20% | — | |
| 26 | SNOW | Snowflake Inc | Stock-Tech | 0.46% | +0.11% | — | |
| 27 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 28 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 0.20% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PATH | Uipath Inc - Class A | +30% | +2.95% | Add |
| 2 | AUTL | Autolus Therapeutics PLC | +1.9% | — | Unchanged |
| 3 | CXM | Sprinklr Inc-a | +1.3% | — | Unchanged |
| 4 | ANNX | Annexon Inc | +1.3% | -3.79% | Trim |
| 5 | LYFT | Lyft Inc-a | +1.1% | — | Unchanged |
| 6 | WK | Workiva Inc | +1% | — | Unchanged |
| 7 | ARWR | Arrowhead Pharmaceuticals In | +1% | +18.44% | Add |
| 8 | AM6 | Amicus Therapeutics Inc | +0.7% | +115.14% | Add |
| 9 | DYN | Dyne Therapeutics Inc | +0.6% | +11.12% | Add |
| 10 | MBX | Mbx Biosciences Inc | +0.5% | -19.41% | Trim |
| 11 | KGEI | Kolibri Global Energy Inc | +0.5% | -1.92% | Trim |
| 12 | KRYS | Krystal Biotech Inc | +0.5% | +142.59% | Add |
| 13 | PHVS | Pharvaris N.V. | +0.5% | — | Unchanged |
| 14 | IMVT | Immunovant Inc | +0.5% | -11.78% | Trim |
| 15 | ALKS | Alkermes plc | +0.5% | +57.54% | Add |
| 16 | CLDX | Celldex Therapeutics Inc | +0.4% | -19.70% | Trim |
| 17 | AXSM | Axsome Therapeutics Inc | +0.3% | -42.02% | Trim |
| 18 | AMLX | Amylyx Pharmaceuticals Inc | +0.2% | +5.65% | Add |
| 19 | SNOW | Snowflake Inc | +0.2% | — | Unchanged |
| 20 | BABA 0.5 06-01-31Bond | Alibaba Group Holding | — | EXIT | Sold out |
| 21 | HYG | Ishr Ibx Usd Hiyld Cb Etf-ui | — | EXIT | Sold out |
| 22 | LARCN 1.75 01-15-27Bond | Lithium Argentina AG | — | EXIT | Sold out |
| 23 | CABO 0 03-15-26Bond | Cable One Inc | — | EXIT | Sold out |
| 24 | PRGS 1 04-15-26Bond | Progress Software CORP | — | EXIT | Sold out |
| 25 | OTLY 9.25 09-14-28Bond | Oatly Group AB | — | EXIT | Sold out |
| 26 | AGCN 0.375 01-15-27Bond | First Majestic Silver | — | EXIT | Sold out |
| 27 | CELC 2.75 08-01-31Bond | Celcuity Inc | — | EXIT | Sold out |
| 28 | TARS | Tarsus Pharmaceuticals Inc | — | EXIT | Sold out |
| 29 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 30 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 31 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 32 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 33 | TECX | Tectonic Therapeutic Inc | — | EXIT | Sold out |
| 34 | HRMY | Harmony Biosciences Holdings | — | NEW | New buy |
| 35 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 36 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 37 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 38 | SLN | Silence Therapeutics Plc-adr | — | NEW | New buy |
| 39 | ACAD | Acadia Pharmaceuticals Inc | — | EXIT | Sold out |
| 40 | HBM | Hudbay Minerals Inc | — | EXIT | Sold out |
| 41 | ZVRA | Zevra Therapeutics Inc | — | NEW | New buy |
| 42 | CCJ | Cameco CORP | — | EXIT | Sold out |
| 43 | RLAY | Relay Therapeutics Inc | — | EXIT | Sold out |
| 44 | ✓ | Avadel Pharmaceuticals PLC ADR | — | NEW | New buy |
| 45 | TECK | Teck Resources Ltd-cls B | — | EXIT | Sold out |
| 46 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 47 | ✓ | Lithium Argentina AG F | — | EXIT | Sold out |
| 48 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 49 | WBI | Waterbridge Infrastruc-cl A | — | EXIT | Sold out |
| 50 | NXE | Nexgen Energy LTD | — | EXIT | Sold out |
According to official SEC Form 13F filings, Tetragon Partners GP Ltd reported a total U.S. public equity portfolio value of $635.1M across 28 disclosed positions in Q4 2025.
During Q4 2025, Tetragon Partners GP Ltd's top holdings by market value included PATH (60.3%)、KGEI (5.8%)、LYFT (4.1%). The largest single position, PATH, represented 60.3% of total portfolio value.
In Q4 2025, Tetragon Partners GP Ltd made 46 total portfolio adjustments, initiating 9 new buys, adding to 7 positions, trimming 6 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.